Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
The post Novartis’ CAR-T drug needs new payment model, says Express Scripts appeared first on Pharmaphorum. https://pharmaphorum.com/news/novartis-car-t-expensive-us-health-system-express-scripts/
How chaos surrounding the GOP’s health-care plan could bring the U.S. closer to single-payer, says Proteus Duxbury. http://www.cnbc.com/2017/06/26/single-payer-health-care-is-closer-than-you-think-commentary.html
(MedPage Today) — Releases mentioning the ACA emphasize negatives https://www.medpagetoday.com/publichealthpolicy/healthpolicy/65351
FORT WASHINGTON, Pa., Feb. 15, 2017 /PRNewswire-USNewswire/ — Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component. Additionally, the importance of inherited cancer genomics was further… http://www.prnewswire.com/news-releases/payers-weigh-the-implications-of-multigene-testing-coverage-in-new-ucsf-study-300407868.html
The change of administrations in Washington, DC may undermine the future of a proposal to revise Medicare Part B drug compensation, a plan that has been widely criticized in the oncological community because of the potential reduction in profit margins it entails. http://www.onclive.com/web-exclusives/coa-declares-early-victory-in-cms-part-b-payment-battle
In its re-interpretation of CMS policy for Medicare Part D drug dispensing, CVS Health has gone against years of allowing in-house physician dispensaries to participate in Medicare Part D. http://www.onclive.com/publications/oncology-business-news/2016/october-2016/cms-backs-up-cvs-network-exclusions-under-part-d